The patent dispute between US-based pharma major Bristol-Myers Squibb (BMS) and Cipla over Entecavir, a combination for treating Hepatitis B, has been settled amicably out of court.
The Intellectual Property Appellate Board (IPAB) on Wednesday, taking into consideration the endorsement by the warring parties, dismissed the original rectification application filed by Cipla against BMS’ patent. The counsels appearing for both the parties informed the IPAB that the matter has been settled out of court in April, 2015. The IPAB bench comprising Justice KN Basha and DPS Parmar, technical member – patent dismissed the application as withdrawn not pressed. The companies requested the terms of settlement has to be kept confidential.